Search PubMed⌕ Search

Biomedical subjects

B A Stuck

Publications and source records attributed to B A Stuck.

21 records · Page 2Linked to original sources

The phosphodiesterase 4 inhibitor roflumilast is effective in the treatment of allergic rhinitis.

BACKGROUND: The beneficial effects of phosphodiesterase 4 (PDE4) inhibitors in allergic asthma have been shown in previous preclinical and clinical studies. Because allergic rhinitis and asthma share several epidemiologic and pathophysiologic factors, PDE4 inhibitors might also be effective in allergic rhinitis. OBJECTIVE: The main objective of this study was to investigate the efficacy of oral roflumilast (500 microg/day) in allergic rhinitis. METHODS: In a randomized, placebo-controlled, double-blinded, crossover study, 25 subjects (16 male, 9 female; median age, 28 years) with histories of allergic rhinitis but asymptomatic at screening received roflumilast (500 microg once daily) and placebo for 9 days each with a washout period of at least 14 days in between treatment periods. In each of the treatment periods, controlled intranasal allergen provocation with pollen extracts was performed daily beginning the third day of treatment, each time approximately 2 hours after study drug administration. Five and 30 minutes after each allergen provocation, rhinal airflow was measured by means of anterior rhinomanometry and the subjective symptoms obstruction, itching, and rhinorrhea were assessed by means of a standardized visual analog scale. RESULTS: Rhinal airflow improved almost consistently during the 9 days of roflumilast treatment, and it was significantly higher at study day 9 on roflumilast in comparison with placebo, a result also found for itching and rhinorrhea. With respect to the subjective obstruction score, a significant difference in comparison with placebo could be demonstrated within 4 days. CONCLUSION: This study shows that a PDE4 inhibitor, roflumilast, effectively controls symptoms of allergic rhinitis. Thus PDE4 inhibitors might be a future treatment option not only in allergic asthma but also in allergic rhinitis or the combination of the 2 diseases.

3',5'-Cyclic-AMP Phosphodiesterases↗

[Excessive weight loss caused by dysphagia in superior laryngeal nerve neuralgia--a case report].

BACKGROUND: Superior laryngeal nerve neuralgia is a very rare disease typically associated with paroxysmal and lancinating pain mostly localised on one side of the laryngeal region and sometimes radiating into the homolateral jaw or ear. The condition is usually idiopathic and treated successfully with carbamazepine. Even if the symptoms are unusual or not typical for superior laryngeal nerve neuralgia, the condition should be considered as a possible diagnosis if there are no other pathological findings. CASE REPORT: In October 1999, a 44-year old man presented a progressive dysphagia. Complaining about increasing problems in swallowing, he started refusing solid food and lost about 50 kg in two and a half years. In addition, he complained about persistent pain in the right laryngeal region, intensified by chewing or swallowing. Extensive investigations produced no pathological findings, especially no neoplastic process or other consuming diseases. After an injection of local anaesthetic near to the right hypothyroid membrane, the symptoms improved dramatically for a few hours and the diagnosis of superior laryngeal neuralgia was made. To confirm the diagnosis we injected sodium chloride as a placebo without any effect. The condition was successfully treated with 200 mg of carbamazepine three times daily without any major side effects. CONCLUSIONS: Even if the symptoms are not typical and dysphagia and weight loss are the outstanding symptoms, superior laryngeal nerve neuralgia should be considered as the possible diagnosis, especially if no other pathological findings are revealed. Injection of local anesthetic is a valuable tool for diagnosing the disease.

Adult↗